Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77) - isoleucine 720 mg in 100 ml

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77) - isoleucine 462 mg in 100 ml

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - isoleucine 534 mg in 100 ml - aminosyn-pf 7%, sulfite-free, (an amino acid injection — pediatric formula) is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring tpn via either central or peripheral infusion routes. parenteral nutrition with aminosyn-pf 7% is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where (1) the alimentary tract by the oral gastrostomy, or jejunostomy route, cannot or should not be used or adequate protein intake is not feasible by these routes, (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutrition support, and vein tolerance. see dosage and administration for additional information. central

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77) - isoleucine 561 mg in 100 ml

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

baxter healthcare corporation - leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), histidine (unii: 4qd397987e) (histidine - unii:4qd397987e), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), tyrosine (unii: 42hk56048u) (tyrosine - unii:42hk56048u), arginine (unii: 94zla3w45f) (arginine - unii:94zla3w45f), proline (unii: 9dlq4ciu6v) (proline - unii:9dlq4ciu6v), alanine (unii: of5p57n2zx) (alanine - unii:of5p57n2zx), glutamic acid (unii: 3kx376gy7l) (glutamic acid - unii:3kx376gy7l), serine (unii: 452vly9402) (serine - unii:452vly9402), glycine (unii: te7660xo1c) (glycine - unii:te7660xo1c), aspartic acid (unii: 30kyc7miai) (aspartic acid - unii:30kyc7miai), taurine (unii: 1eqv5mly3d) (taurine - unii:1eqv5mly3d), cysteine hydrochloride (unii: zt934n0x4w) (cysteine - unii:k848jz4886) - leucine 1.4 g in 100 ml - premasol 10% injection is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring tpn via either central or peripheral infusion routes. parenteral nutrition with premasol 10% injection is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where: (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance (see dosage and administration). central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted infants, or those requiring long-term parenteral nutrition. for moderately catabolic or depleted patients in whom the central venous route is not indicated, diluted amino acid solutions mixed with 5-10% dextrose solutions may be infused by peripheral vein, supplemented, if desired, with fat emulsion. premasol 10% injection is contraindicated in patients with untreated anuria, hepatic coma, inborn errors of amino acid metabolism, including those involving branched chain amino acid metabolism such as maple syrup urine disease and isovaleric acidemia, or hypersensitivity to one or more amino acids present in the solution.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

b. braun medical inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - isoleucine 0.69 g in 100 ml - parenteral nutrition with 10% freamine® iii (amino acid injection) is indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric patients where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. dosage, route of administration, and concomitant infusion of nonprotein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance. see warnings, precautions, pediatric use , and dosage and administration. central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted patients, or those requiring long-term

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

b. braun medical inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - isoleucine 0.76 g in 100 ml - parenteral nutrition with 6.9% freamine hbc® (amino acid injection) is indicated to prevent nitrogen loss or treat negative nitrogen balance in adults where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) nitrogen homeostasis is substantially impaired as with severe trauma or sepsis. dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance. see dosage and administration . central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted patients, or those requiring long-term parenteral nutrition. for moderately catabolic or deplet

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

b. braun medical inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - isoleucine 0.9 g in 100 ml - hepatamine® is indicated for the treatment of hepatic encephalopathy in patients with cirrhosis or hepatitis. hepatamine® provides nutritional support for patients with these diseases of the liver who require parenteral nutrition and are intolerant of general purpose amino acid injections, which are contraindicated in patients with hepatic coma. hepatamine® is contraindicated in patients with anuria, inborn errors of amino acid metabolism, especially those involving branched chain amino acid metabolism such as maple syrup urine disease and isovaleric acidemia, or hypersensitivity to one or more amino acids present in the solution.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

baxter healthcare corporation - leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), lysine hydrochloride (unii: jnj23q2com) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), histidine (unii: 4qd397987e) (histidine - unii:4qd397987e), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (un - leucine 730 mg in 100 ml - travasol is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. travasol may be used to treat negative nitrogen balance in patients. the use of travasol is contraindicated in: risk summary limited published data with injectable amino acids solutions, including travasol in pregnant women are not sufficient to inform a drug associated risk for adverse developmental outcomes. however, malnutrition in pregnant women is associated with adverse maternal and fetal outcomes [see clinical considerations]. animal reproduction studies have not been conducted with injectable amino acids solutions, including travasol. the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. however, the background risk in the u.s. general population of major birth defects is 2 to 4% and of miscar

United Kingdom - Inggeris - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - l-isoleucine - oral solution - 10mg/1ml